Trastuzumab Deruxtecan (DS-8201a) Versus Investigator’s Choice for HER2-low Breast Cancer That Has Spread or Cannot be Surgically Removed [DESTINY-Breast04]

Inclusion Criteria:

Is the age of majority in their country

Has pathologically documented breast cancer that:

Is unresectable or metastatic
Has low-HER2 expression defined as IHC 2+/ISH- or IHC 1+ (ISH- or untested)
Is HR-positive or HR-negative
Has progressed on, and would no longer benefit from, endocrine therapy
Has been treated with 1 to 2 prior lines of chemotherapy/adjuvant in the metastatic setting
Was never previously HER2-positive (ICH 3+ or ISH+) on prior pathology testing (per American Society of Clinical Oncology-College of American Pathologists [ASCO-CAP] guidelines)
Has documented radiologic progression (during or after most recent treatment)

Has adequate archival tumor samples available or is wiling to provide fresh biopsies prior to randomization for:

assessment of HER2 status
assessment of post-treatment status
Has at least 1 protocol-defined measurable lesion
Has protocol-defined adequate cardiac, bone marrow, renal, hepatic and blood clotting functions
Male and female participants of reproductive/childbearing potential, agrees to follow instructions for method(s) of contraception and agrees to avoid preserving ova or sperm for at least 4.5 months after treatment (or longer, per locally approved labels)

Exclusion Criteria:

Is ineligible for all options in the physician's choice arm
Has breast cancer ever assessed with high-HER2 expression
Has previously been treated with any anti-HER2 therapy, including an antibody drug conjugate
Has uncontrolled or significant cardiovascular disease
Has spinal cord compression or clinically active central nervous system metastases
Has history of (noninfectious) interstitial lung disease (ILD)/pneumonitis that required steroids, has current ILD/pneumonitis, or suspected ILD/pneumonitis that cannot be ruled out by imaging at screening
Has any medical history or condition that per protocol or in the opinion of the investigator is inappropriate for the study